Teva Pharmaceutical Industries Limited

NYSE:TEVA Voorraadrapport

Marktkapitalisatie: US$19.0b

Teva Pharmaceutical Industries Beheer

Beheer criteriumcontroles 2/4

De CEO Teva Pharmaceutical Industries is Richard Francis, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 25.71M, bestaande uit 6.2% salaris en 93.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.011% van de aandelen van het bedrijf, ter waarde $ 2.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 7.3 jaar.

Belangrijke informatie

Richard Francis

Algemeen directeur

US$25.7m

Totale compensatie

Percentage CEO-salaris6.2%
Dienstverband CEO1.8yrs
Eigendom CEO0.01%
Management gemiddelde ambtstermijn2.7yrs
Gemiddelde ambtstermijn bestuur7.3yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Mar 26
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Jan 07
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way

Dec 11
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

Sep 09
Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Jun 06
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Feb 20
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

Analyse CEO-vergoeding

Hoe is Richard Francis's beloning veranderd ten opzichte van Teva Pharmaceutical Industries's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$959m

Jun 30 2024n/an/a

-US$453m

Mar 31 2024n/an/a

-US$478m

Dec 31 2023US$26mUS$2m

-US$559m

Compensatie versus markt: De totale vergoeding ($USD 25.71M ) Richard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Richard te vergelijken met de prestaties van het bedrijf.


CEO

Richard Francis (56 yo)

1.8yrs

Tenure

US$25,706,880

Compensatie

Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Richard Francis
President1.8yrsUS$25.71m0.011%
$ 2.1m
Eliyahu Kalif
Executive VP & CFO4.9yrsUS$4.94m0.064%
$ 12.2m
Mark Sabag
Executive Vice President of International Markets Commercial3.3yrsUS$3.73m0.028%
$ 5.3m
Richard Daniell
Executive Vice President of European Commercial7yrsUS$5.16m0%
$ 0
Matthew Shields
Executive Vice President of Global Operationsless than a yeargeen gegevensgeen gegevens
Amir Weiss
Senior VP & Chief Accounting Officer3yrsgeen gegevens0.00046%
$ 87.6k
Ran Meir
Head of Investor Relationsno datageen gegevensgeen gegevens
Kathleen Veit
Senior Vice President2.3yrsgeen gegevensgeen gegevens
David Mcavoy
Executive VP & Chief Legal Officerless than a yeargeen gegevensgeen gegevens
Placid Jover
Executive VP & CHROless than a yeargeen gegevensgeen gegevens
Kevin Mannix
Senior Vice President of Investor Relationsno datageen gegevensgeen gegevens
Nir Baron
Senior VP & Chief Internal Auditor10.5yrsgeen gegevensgeen gegevens

2.7yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TEVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Richard Francis
Presidentno dataUS$25.71m0.011%
$ 2.1m
Sol Barer
Independent Chairman of the Board9.8yrsUS$539.99k0.036%
$ 6.9m
Amir Elstein
Independent Director15.8yrsUS$340.00k0.18%
$ 35.2m
Gerald Lieberman
Independent Director9.2yrsUS$355.00k0.0094%
$ 1.8m
Roberto Mignone
Independent Director7.3yrsUS$340.00k0.0084%
$ 1.6m
Rosemary Crane
Independent Director9.2yrsUS$330.00k0.0091%
$ 1.7m
Janet Vergis
Independent Director4.4yrsUS$325.46k0.0056%
$ 1.1m
Tal Zaks
Independent Director3.1yrsUS$330.00k0.0043%
$ 826.6k
Perry Nisen
Independent Director7.3yrsUS$327.87k0.0084%
$ 1.6m
Ronit Satchi-Fainaro
Independent Director6.4yrsUS$315.25k0.0078%
$ 1.5m
Varda Shalev
Independent Director1.2yrsUS$176.66k0.0011%
$ 217.1k

7.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TEVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).